Caractéristiques cliniques, évolution à long terme et facteurs prédictifs de rechute après arrêt de l'Imatinib au cours de leucémie chronique à éosinophiles associée au …
J Rohmer, JS Bladé, PC Makhoul, V Cottin… - La Revue de Médecine …, 2020 - Elsevier
Introduction La leucémie chronique à éosinophiles associée au transcrit FIP1L1-PDGFRA
(LCE F/P) est un syndrome hyperéosinophilique (SHE) clonal qui présente une grande …
(LCE F/P) est un syndrome hyperéosinophilique (SHE) clonal qui présente une grande …
Caractéristiques cliniques, évolution à long terme et facteurs prédictifs de rechute après arrêt de l'Imatinib au cours de leucémie chronique à éosinophiles associée au …
J Rohmer, JS Bladé, PC Makhoul, V Cottin… - La Revue de Médecine …, 2021 - Elsevier
Introduction La leucémie chronique à éosinophiles associéeau transcrit FIP1L1-PDGFRA
(LCE F/P) est un syndrome hyperéosinophilique (SHE) clonal qui présente une grande …
(LCE F/P) est un syndrome hyperéosinophilique (SHE) clonal qui présente une grande …
[HTML][HTML] Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China
SQ Qu, TJ Qin, ZF Xu, Y Zhang, XF Ai, B Li, HL Zhang… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background The FIP1L1/PDGFRA (F/P) fusion gene is the most common clonal genetic
abnormality of chronic eosinophilic leukemia (CEL). Tyrosine kinase inhibitors (TKI), such as …
abnormality of chronic eosinophilic leukemia (CEL). Tyrosine kinase inhibitors (TKI), such as …
The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases
F Legrand, A Renneville, E MacIntyre, S Mastrilli… - Medicine, 2013 - journals.lww.com
Imatinib is the treatment of choice for FIP1L1/PDGFRA (F/P)-associated chronic eosinophilic
leukemia (F/P+ CEL), but its optimal dosing, duration, and possibility of discontinuation are …
leukemia (F/P+ CEL), but its optimal dosing, duration, and possibility of discontinuation are …
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
AD Klion, J Robyn, I Maric, W Fu… - Blood, The Journal …, 2007 - ashpublications.org
Although imatinib is clearly the treatment of choice for FIP1L1/PDGFRA-positive chronic
eosinophilic leukemia (CEL), little is known about optimal dosing, duration of treatment, and …
eosinophilic leukemia (CEL), little is known about optimal dosing, duration of treatment, and …
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive …
JV Jovanovic, J Score, K Waghorn… - Blood, The Journal …, 2007 - ashpublications.org
Abstract The FIP1L1-PDGFRA fusion gene is a recurrent molecular lesion in eosinophilia-
associated myeloproliferative disorders, predicting a favorable response to imatinib …
associated myeloproliferative disorders, predicting a favorable response to imatinib …
Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript
G Helbig, A Soja, A Świderska, M Hus… - Leukemia & …, 2016 - Taylor & Francis
A subset of patients with hypereosinophilic syndrome (HES) may harbor an interstitial
deletion in chromosome 4, leading to the creation of the FIP1L1-PDGFRA (F/P+) fusion gene …
deletion in chromosome 4, leading to the creation of the FIP1L1-PDGFRA (F/P+) fusion gene …
Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia
G Helbig, A Moskwa, M Hus, J Piszcz… - Cancer chemotherapy …, 2011 - Springer
The exquisite response to imatinib mesylate in patients with chronic eosinophilic leukaemia
(CEL) harbouring the FIP1L1-PDGFRa (F/P) fusion transcript has been well documented [1 …
(CEL) harbouring the FIP1L1-PDGFRa (F/P) fusion transcript has been well documented [1 …
Treatment-free remission in FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation
G Metzgeroth, J Schwaab, N Naumann… - Blood …, 2020 - ashpublications.org
Abstract FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia (MLN-
eo) are exquisitely sensitive to imatinib. Almost all patients achieve a complete molecular …
eo) are exquisitely sensitive to imatinib. Almost all patients achieve a complete molecular …
Incidence et caractéristiques des AVC ischémiques au cours des Syndromes Hyperéosinophiliques clonaux: toxicité vasculaire des éosinophiles?
J Tennenbaum, M Groh, L Venditti, FC Gazeau… - La Revue de Médecine …, 2020 - Elsevier
Introduction La leucémie chronique à éosinophiles (LCE) associée au réarrangement FIP1-
PDGRFα (F/P) est un syndrome hyperéosinophilique (SHE) responsable d'une prolifération …
PDGRFα (F/P) est un syndrome hyperéosinophilique (SHE) responsable d'une prolifération …